E. Duran Et Al. , "Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al.," Clinical and experimental rheumatology , vol.41, 2023
Duran, E. Et Al. 2023. Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al.. Clinical and experimental rheumatology , vol.41 .
Duran, E., Yildirim, B. E. S., & Karadağ, Ö., (2023). Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al.. Clinical and experimental rheumatology , vol.41.
Duran, EMİNE, Beste Ekin Sandalcı Yildirim, And Ömer Karadağ. "Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al.," Clinical and experimental rheumatology , vol.41, 2023
Duran, EMİNE Et Al. "Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al.." Clinical and experimental rheumatology , vol.41, 2023
Duran, E. Yildirim, B. E. S. And Karadağ, Ö. (2023) . "Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al.." Clinical and experimental rheumatology , vol.41.
@article{article, author={EMİNE SARIYILDIZ Et Al. }, title={Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al.}, journal={Clinical and experimental rheumatology}, year=2023}